CA2583794A1 — Compositions for intranasal administration
Assigned to JNTL Consumer Health I Switzerland GmbH · Expires 2006-04-20 · 20y expired
What this patent protects
The present invention relates to pharmaceutical compositions for administration to the nasal tract. In particular, the invention relates to dry powder compositions comprising cellulose, and in particular hyroxypropylmethylcellulose (HPMC), and one or more therapeutic agents. It h…
USPTO Abstract
The present invention relates to pharmaceutical compositions for administration to the nasal tract. In particular, the invention relates to dry powder compositions comprising cellulose, and in particular hyroxypropylmethylcellulose (HPMC), and one or more therapeutic agents. It has been shown that administration of HPMC to the nasal cavity is capable of enhancing natural mucus. These powders, and the gel that forms when they are administered to the nasal tract, have now surprisingly been found to be a very effective way of intranasally administering therapeutic agents, and in particular, herbal or homeopathic agents.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.